PT - JOURNAL ARTICLE AU - Laurent Savale AU - Marloes Huitema AU - Oksana Shlobin AU - Vasilis Kouranos AU - Steven D. Nathan AU - Hiliaro Nunes AU - Rohit Gupta AU - Jan C. Grutters AU - Daniel A. Culver AU - Marco C. Post AU - Daniel Ouellette AU - Elyse E. Lower AU - Tamara Al-Hakim AU - Athol U Wells AU - Marc Humbert AU - Robert P. Baughman TI - WASOG statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertension AID - 10.1183/16000617.0165-2021 DP - 2022 Mar 31 TA - European Respiratory Review PG - 210165 VI - 31 IP - 163 4099 - http://err.ersjournals.com/content/31/163/210165.short 4100 - http://err.ersjournals.com/content/31/163/210165.full SO - EUROPEAN RESPIRATORY REVIEW2022 Mar 31; 31 AB - Sarcoidosis-associated pulmonary hypertension (SAPH) is an important complication of advanced sarcoidosis. Over the past few years, there have been several studies dealing with screening, diagnosis and treatment of SAPH. This includes the results of two large SAPH-specific registries. A task force was established by the World Association of Sarcoidosis and Other Granulomatous disease (WASOG) to summarise the current level of knowledge in the area and provide guidance for the management of patients. A group of sarcoidosis and pulmonary hypertension experts participated in this task force. The committee developed a consensus regarding initial screening including who should undergo more specific testing with echocardiogram. Based on the results, the committee agreed upon who should undergo right-heart catheterisation and how to interpret the results. The committee felt there was no specific phenotype of a SAPH patient in whom pulmonary hypertension-specific therapy could be definitively recommended. They recommended that treatment decisions be made jointly with a sarcoidosis and pulmonary hypertension expert. The committee recognised that there were significant defects in the current knowledge regarding SAPH, but felt the statement would be useful in directing future studies.Sarcoidosis-associated pulmonary hypertension is a significant cause of morbidity and mortality. A guide to screening, diagnosis and treatment has been developed by a team of experts. https://bit.ly/3FzOcgb